Y mAbs Therapeutics

Y mAbs Therapeutics — Q1 2025 Earnings Presentation

17 slides from Y mAbs Therapeutics's earnings presentation, May 13, 2025

  1. Slide 1: Q1 2025 Financial Results

    Q1 2025 Financial Results May 13, 2025

  2. Slide 2: Disclaimer

    Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical f

  3. Slide 3: Q1 2025 Business Highlights

    Mike Rossi President and Chief Executive Officer Q1 2025 Business Highlights 3

  4. Slide 4: Agenda

    Agenda Q1 2025 Business Highlights 1 Mike Rossi, President and Chief Executive Officer DANYELZA Global Performance 2 Doug Gentilcore, DANYELZA Business Unit Head Q1 2025 Financials and Guidance Discussion 3 Peter Pfreundschuh, Chief Financial Officer Q&A 4 All 4

  5. Slide 5: Q1 2025 and Recent Corporate Highlights

    Q1 2025 and Recent Corporate Highlights ✓ Executed business realignment of ✓ First patient dosed in CD38-SADA Phase 1 DANYELZA and Radiopharmaceuticals clinical trial in r/r NHL (Trial 1201) ✓ Q1 2025 DANYELZA Net Product Revenues ✓ Completed Part A of GD2-SADA Phase 1 of $20.9M, higher end of guida

  6. Slide 6: Key Updates During Radiopharmaceutical R&D update on May 28th

    Key Updates During Radiopharmaceutical R&D update on May 28th* Ongoing Trial 1001 (GD2-SADA) Platform Optimization Radiopharmaceutical Pipeline Phase 1: Optimization Workstreams Expansion Opportunities and Part A Data Readout Underway Timelines* ✓ Safety profile and tolerability of • Optimize chelat

  7. Slide 7: DANYELZA Global Performance

    Doug Gentilcore DANYELZA Business Unit Head DANYELZA Global Performance 7

  8. Slide 8: Q1 2025 DANYELZA Global Commercial Update

    Q1 2025 DANYELZA Global Commercial Update • Q1 2025 DANYELZA Net Product Revenues of $20.9M,  8% YoY • U.S. commercial strategy focused on accelerating advocacy, increasing new patient starts, and highlighting financial advantages of DANYELZA • DANYELZA added to NCCN* guidelines, in combination wit

  9. Slide 9: Financial Results and Guidance Discussion

    Peter Pfreundschuh Chief Financial Officer Q1 2025 Financials and Guidance Discussion 9

  10. Slide 10: Key Q1 2025 Financial Highlights: Revenue

    Key Q1 2025 Financial Highlights Revenue Three months ended Mar 31, 2025 2024 Percent Change Net product revenue $20.9 M $19.4 M  8% License revenue – $0.5 M Total revenues $20.9 M $19.9 M  5% 10

  11. Slide 11: Key Q1 2025 Financial Highlights: Operating Expenses

    Key Q1 2025 Financial Highlights Operating Expenses Three months ended Mar 31, 2025 2024 Percent Change License royalties – $0.05 M Research & development $11.4 M $13.3 M  14% Selling, general & admin $13.1 M* $11.4 M  15% Total OpEx $24.4 M $24.7 M *Company had approximately $0.5M restructuring c

  12. Slide 12: Key Q1 2025 Financial Highlights: Net Loss

    Key Q1 2025 Financial Highlights Net Loss Three months ended Mar 31, 2025 2024 Percent Change Net loss $(5.2) M $(6.6) M  22% Net loss per basic, diluted $(0.12) $(0.15) share 12

  13. Slide 13: Selected Financial Information by Reportable Segment

    Key Q1 2025 Financial Highlights Selected Financial Information by Reportable Segment* Three Months Ended March 31, 2025 2024 DANYELZA RIT Total DANYELZA RIT Total REVENUES Net product revenue $ 20,904 $ — $ 20,904 $ 19,431 $ — $ 19,431 License revenue — — — 500 — 500 Total revenues 20,904 — 20,904

  14. Slide 14: Responsible stewards of capital

    Key Q1 2025 Financial Highlights Responsible stewards of capital As of Mar 31, 2025 Dec 31, 2024 Cash and cash equivalents $60.3 M $67.2 M Anticipated cash runway into 2027* *This estimate reflects the Company's current business plan and is supported by assumptions that may prove to be inaccurate, s

  15. Slide 15: Financial Guidance for Q2 and Full Year 2025

    Financial Guidance for Q2 and Full Year 2025 FY 2025 Total Expected Revenues: $75 million to $90 million FY 2025 Total Expected Operating Costs and Expenses*: $116 million to $121 million FY 2025 Total Expected Annual Cash Investment: $25 million to $30 million Q2 2025 Total Expected Revenues: $17 m

  16. Slide 16: Q&A

    Q&A Mike Rossi Doug Gentilcore President and DANYELZA Business Chief Executive Officer Unit Head Peter Pfreundschuh Chief Financial Officer 16

  17. Slide 17: Thank You

    Thank You

Y-mAbs Therapeutics — Q1 2025 Earnings Presentation on 6ix